Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Keyphrases

• COVID-19 100%
• COVID-19 Treatment 100%
• Platform Trials 100%
• Randomized Evaluation 100%
• Updated Meta-analysis 100%
• Baricitinib 100%
• Usual Care 50%
• Janus Kinase Inhibitors 50%
• Meta-analysis 20%
• Mortality Rate 20%
• Health Research 10%
• Once-daily 10%
• Randomized Controlled Trial 10%
• Standard of Care 10%
• Possible Treatments 10%
• Rate Ratio 10%
• Corticosteroids 10%
• Medical Research Council 10%
• Risk of Death 10%
• National Institutes of Health 10%
• Intention-to-treat 10%
• Care Groups 10%
• Group Care 10%
• 28-day Mortality 10%
• Non-COVID-19 10%
• Thrombosis 10%
• Safety Outcomes 10%
• Age-adjusted Rate 10%
• Janus Kinase 10%
• Randomized Evidence 10%
• Tocilizumab 10%

Nursing and Health Professions

• Meta Analysis 100%
• Baricitinib 100%
• Janus Kinase Inhibitor 50%
• Rate Ratio 30%
• Mortality Rate 20%
• Health Care Quality 10%
• Intention to Treat Analysis 10%
• Randomization 10%
• National Health Organization 10%
• Tocilizumab 10%
• Janus Kinase 10%
• Care Group 10%
• Thrombosis 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Baricitinib 100%
• Janus Kinase Inhibitor 50%
• Mortality Rate 20%
• Thrombosis 10%
• Tocilizumab 10%
• Janus Kinase 10%
• Randomized Controlled Trial 10%